Dealmaking When Pharma's the Only Game in Town
With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.
You may also be interested in...
When the IPO spigot runs dry, there’s M&A aplenty, and when the IPO wine is flowing, M&A slows down, right? FOTF tackles some conventional wisdom; plus deals from Acadia, Neurocrine, Aquinox, and Human Longevity.
Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.
Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.